~~<i id='2AE8980452'><strike id='2AE8980452'><tt id='2AE8980452'><pre id='2AE8980452'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

explore

author：explore 2025-08-11 02:12:31 - browse：76699

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Albert Bourla of Pfizer: worst biopharma CEO of 2023

knowledge

focus

knowledge

explore

focus

hotspot

CytokineticsCEORobertBlumspokelastweekatatalkduringSTAT’sBreakthroughSummitWestinSanFrancisco.SarahG

WSS

Medicare drug price negotiation hasn't dried up venture capital

Medicare Advantage beneficiaries sue Humana over algorithm use

FDA poised to publish guidelines for clinical trial diversity

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Prime Medicine, Myeloid Therapeutics clash over genome

leisure time

explore

knowledge

Heart attack and stroke risk calculators need revising

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Medicare proposal to cover medical devices draws a mixed reaction

Biogen joins immunology wave with $1.15 billion acquisition of HI

Walensky prepares to leave CDC — and Congress — behind

Prime Medicine, Myeloid Therapeutics clash over genome

State Dept. review finds Biden bears some blame for Afghanistan failures

Bristol Myers buys into radiopharmaceuticals with RayzeBio

United colonoscopy coverage change 'may cost lives,' doctors say

Making the case for fair compensation in clinical trials

focus

As a primary care physician, here's how I hope to partner with AI

Medicare Advantage beneficiaries sue Humana over algorithm use

Why health care costs have stayed mostly flat since 2010

Virtual care provider acquires bankrupt Pear's prescription apps

Drinking less cuts risk of oral cavity, esophageal cancer: Report

What STAT readers think about the FDA and patient advocacy

knowledge

explore

focus

hotspot